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New Antimicrobial Potential and 
Structural Properties of PAFB: A 
Cationic, Cysteine-Rich Protein 
from Penicillium chrysogenum Q176
Anna Huber1, Dorottya Hajdu2, Doris Bratschun-Khan1, Zoltán Gáspári3, Mihayl Varbanov4, 
Stéphanie Philippot4, Ádám Fizil2, András Czajlik2, Zoltán Kele5, Christoph Sonderegger1, 
László Galgóczy1,6, Andrea Bodor7, Florentine Marx  1 & Gyula Batta2
Small, cysteine-rich and cationic proteins with antimicrobial activity are produced by diverse organisms 
of all kingdoms and represent promising molecules for drug development. The ancestor of all industrial 
penicillin producing strains, the ascomycete Penicillium chryosgenum Q176, secretes the extensively 
studied antifungal protein PAF. However, the genome of this strain harbours at least two more genes 
that code for other small, cysteine-rich and cationic proteins with potential antifungal activity. In 
this study, we characterized the pafB gene product that shows high similarity to PgAFP from P. 
chrysogenum R42C. Although abundant and timely regulated pafB gene transcripts were detected, 
we could not identify PAFB in the culture broth of P. chrysogenum Q176. Therefore, we applied a 
P. chrysogenum-based expression system to produce sufficient amounts of recombinant PAFB to 
address unanswered questions concerning the structure and antimicrobial function. Nuclear magnetic 
resonance (NMR)-based analyses revealed a compact β-folded structure, comprising five β-strands 
connected by four solvent exposed and flexible loops and an “abcabc” disulphide bond pattern. We 
identified PAFB as an inhibitor of growth of human pathogenic moulds and yeasts. Furthermore, 
we document for the first time an anti-viral activity for two members of the small, cysteine-rich and 
cationic protein group from ascomycetes.
The increasing incidence of fatal microbial infections due to the development of resistance against licensed anti-
microbial drugs raises a strong demand for new antimicrobial treatment strategies. Filamentous ascomycetes are 
a rich source of antimicrobial bio-molecules that have the potential for wide application in medicine and agricul-
ture to prevent and treat microbial infections1. As such, the industrially relevant fungus Penicillium chrysogenum 
is not only a well-known producer of the β-lactam antibiotic penicillin, but also secretes small, cysteine-rich and 
cationic proteins with antimicrobial activity. P. chrysogenum is an ideal producer of bio-products with beneficial 
potential to mankind as it is fermentable and bulk production is easy and cheap2. Most importantly, it is recog-
nized as a “safe organism” by the US Food and Drug Administration.
The P. chrysogenum strain Q176 is the ancestor of all industrial strains used for penicillin production today2,3 
and of the strains Wisconsin 54-12554 and P2niaD185, whose genomes were sequenced and are publicly availa-
ble. P. chrysogenum Q176 secretes the antifungal protein PAF whose structural and functional properties have 
been extensively studied6–8. PAF represents a promising bio-molecule for novel antifungal drug development as 
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it is stable against proteolytic degradation, thermo-resistant and active within a broad pH range9, and shows no 
cytotoxic effects in vitro10 or in vivo11,12. Furthermore, PAF could serve as a potential bio-pesticide in agriculture 
to impede infection by plant-pathogenic fungi13.
Genome mining in the strain Wisconsin 54-1255 for nucleotide (nt) sequences coding for other small, 
cysteine-rich and cationic proteins revealed that this P. chrysogenum strain harbours - apart from the paf gene 
(NCBI accession no. Pc24g00380)14 - two more genes that code for proteins with potential antimicrobial activity: 
Pc21g12970 and Pc12g08290. The product of the first gene (NCBI accession no. XP_002568323) is identical to the 
Pc-Arctin isolated from the arctic P. chrysogenum strain A09615, which represents an orthologue of the “bubble 
protein” isolated from the exudate of Penicillium brevicompactum15,16. The product of the second gene (GeneBank 
accession no. CAP80456) is orthologous to PgAFP identified in the supernatant of P. chrysogenum strain RP42C, 
originally isolated from dry-cured ham by Rodríguez-Martín et al.17. Thus, the genome of P. chrysogenum 
Wisconsin 54-1255 and its progenitor strain Q176 contain at least three genes that code for proteins with reported 
antifungal activity. This represents a unique chance to investigate their function within one organism.
PAF, PgAFP and Pc-Arctin have in common that they are encoded as prepro-proteins containing a signal pep-
tide followed by a pro-sequence, both of which are removed during the protein maturation process for secretion 
into the culture supernatant14,15,17. The mature proteins are cationic due to a high content of amino acids (aa) with 
positively charged side-chains. Phylogenetic analyses suggested a classification of the three proteins into different 
groups, whereby Pc-Arctin is grouped more distantly from PAF and PgAFP1,18.
While the predicted PgAFP-orthologous protein from P. chrysogenum Q176 has not been isolated and char-
acterized to date, a high thermo-, pH- and protease stability has been reported for the mature PgAFP of strain 
RP42. Potent growth inhibitory activity against toxigenic moulds on dry-ripened sausages renders this protein 
interesting for the control of unwanted food contamination19.
In the present study, we isolated and studied the PgAFP orthologous protein from P. chrysogenum Q176 and 
addressed unanswered questions concerning its 3D solution structure, antimicrobial specificity and mode of 
action. To distinguish between the two proteins originating from the two different P. chrysogenum strains Q176 
and RP42 we named the protein from strain Q176 P. chrysogenum AntiFungal protein B (PAFB), in analogy to 
the nomenclature of the already extensively studied homologous protein PAF from P. chrysogenum Q17614. We 
adapted the recently described P. chrysogenum-based expression system20 to generate sufficient amounts of PAFB 
for functional and structural characterization. The use of the paf-deficient P. chrysogenum Q176 strain (∆paf) as 
recipient ensured optimal high yield PAFB production by avoiding co-expression of the related antifungal protein 
PAF. We identified a disulphide-bond stabilized and compact β-folded structure of PAFB and found - apart from 
a growth inhibitory activity against moulds and yeasts - anti-viral activity, which has never been reported before 
for any member of the small, cationic and cysteine-rich protein group from ascomycetes.
Results
The pafB gene transcription. Our efforts failed so far to identify PAFB in the supernatant or cell extracts of 
P. chrysogenum Q176 grown under standard conditions (shaking culture in minimal medium MM at 25 °C for up 
to 6 days) (Fig. 1). The same was true for the P. chrysogenum strain ∆paf that lacks the PAF-encoding gene21. We 
examined this mutant to increase the chance to identify PAFB in the absence of PAF (data not shown). Therefore, 
we performed Northern blot analyses to determine the abundance and timing of pafB transcription. Surprisingly, 
we found that pafB mRNA was detectable in P. chrysogenum Q176 shaking cultures with an expression maximum 
at 48 h after inoculation and a subsequent decrease in transcript amount upon further incubation time (Fig. 1a).
In contrast, gene transcripts of paf could be detected from 48 h after inoculation onwards and transcription 
reached its maximum at 72 h (Fig. 1b). This expression pattern correlated with the secretion of PAF protein into 
the culture broth of P. chrysogenum Q176 during the stationary growth phase as reported14. This result was con-
firmed by Western blot by using a specific anti-PAF antibody22 (Fig. 1c, Supplementary Methods).
Incorrect mRNA processing could result in defective protein translation and the production of nonsense 
protein products that are readily degraded23,24. Therefore, we next investigated if the pafB mRNA was correctly 
spliced. The verification of the pafB mRNA sequence was done by cDNA synthesis, PCR amplification of the 
pafB specific transcript and subsequent Sanger sequencing. The obtained sequence matched that of the exons 
of the pafB fragment (Pc24g00380) from the P. chrysogenum Wisconsin 54-1255 genome4 and yielded an intact 
pafB open reading frame indicating correct splicing (Supplementary Fig. S1). Similar to the paf gene14, two short 
introns (63 nt and 62 nt in length, respectively) are present in pafB that contain the consensus 5′-splice donor 
site (GT) and the consensus 3′-splice acceptor site (AG). A consensus sequence for the internal putative lar-
iat formation element (RCTRAC) can be found in the first intron, but not in the second non-coding sequence 
(Supplementary Fig. S1).
The nt sequence of the pafB cDNA (deposited at European Nucleotide Archive (ENA), accession no. 
LT854946) codes for a 92 aa protein (Supplementary Table S1). Comparison of the PAFB primary sequence with 
that of the orthologous PgAFP revealed that PAFB differed in three aa, resulting in 97% identity of both proteins 
(Fig. 2). A histidine to glutamine substitution at position 2 resides in the pre-sequence, serine to asparagine and 
threonine to arginine substitutions at positions 19 and 23, respectively, occur in the pro-sequence (Fig. 2a). The 
predicted mature PAFB protein exhibited 100% identity with the mature PgAFP (Fig. 2b). The similarity of PAFB 
with PAF was 43% for the prepro-proteins and 35% for the mature proteins (Fig. 2b).
Recombinant expression and purification of PAFB. As we could not detect and isolate PAFB from 
the P. chrysogenum Q176 culture supernatant, we employed the P. chrysogenum-based expression system20 to 
produce recombinant PAFB for structural analysis and functional tests. To this end, the P. chrysogenum Δpaf 
strain was transformed with a PstI-linearized plasmid carrying the pafB gene under the control of the strong paf 
promoter20. Positively transformed, ptrA-resistant P. chrysogenum clones were tested for highest protein secretion 
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over a time course of 96 h using small-scale fermentation (data not shown). Southern blot experiments with the 
best PAFB producer clone (P. chrysogenum pafB) revealed multiple random integration events of the transform-
ing DNA into the fungal genome (Supplementary Fig. S2). This clone was selected and cultivated under large scale 
culture conditions.
PAFB was purified from the cell-free culture broth by a single-step chromatography. A protein yield of 
61 ± 11 mg/L supernatant was reached. Purity and identity of PAFB were verified by sodium-dodecyl-sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) and electrospray ionization mass spectrometry (ESI-MS), 
respectively (Fig. 3). On the SDS-PA gels one single band for PAFB was visible in the elution fractions (Fig. 3a). 
ESI-MS detected one main peak corresponding to an average mass of 6.49 kDa, which represented full-length 
PAFB (Fig. 3b). Two smaller peaks corresponding to 6.37 kDa and 6.29 kDa correlated with two N-terminally 
truncated PAFB forms: the 6.37 kDa peak corresponded to a variant without the N-terminal leucine and the 
6.29 kDa peak to a form that lacked the N-terminal residues leucine and serine (Fig. 3b; Supplementary Table S1). 
The average molecular masses of all three peaks matched the calculated theoretical molecular masses (ProtParam 
tool of ExPASy)25 of the oxidized protein forms indicating the presence of three intra-molecular disulphide bonds 
in all three PAFB protein variants. They all lacked any post-translational modifications, except for the cleavage of 
the prepro-sequence, as reported for wild-type PAF20.
Figure 1. Expression of pafB and paf in P. chrysogenum Q176 submerse cultures. Samples were taken after 24, 
48, 72, 96, 120 and 144 h of incubation at 25 °C. For Northern blot analysis 10 µg total RNA were loaded per 
lane on a 1.2% denaturing agarose gel, blotted and hybridized with a (a) pafB or (b) paf specific DIG-labelled 
probe. Ethidium bromide-stained 26 S and 18 S rRNA is shown as loading control. (c) For Western blot analysis, 
25 µL of 10-fold concentrated culture supernatants were loaded per lane, size fractionated on a 18% (w/v) SDS-
polyacrylamide gel and transferred on a nitrocellulose membrane. A polyclonal antibody was used for specific 
PAF detection. (c) purified PAF (1 µg) was loaded as a control. Gels and blots in (a), (b) and (c) were cropped for 
clarity. Full-length gels and blots are included in the Supplementary Information.
Figure 2. ClustalW alignment of the (a) prepro-sequences and (b) sequences of the mature proteins PAFB, 
PgAFP (UniProt ID: D0EXD3) and PAF (Uniprot ID: Q01701). Alignment was performed using the software 
BioEdit Sequence Alignment Editor.
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We used the purified recombinant PAFB to generate polyclonal anti-PAFB antibodies with the aim to identify 
PAFB at higher specificity and sensitivity in the supernatant and cell extract of P. chrysogenum Q176 shaking cul-
tures by Western blot technique (Supplementary Methods). The polyclonal anti-PAFB antibodies specifically rec-
ognized recombinant PAFB, but not PAF in Western blots (Supplementary Fig. S3). However, no PAFB-specific 
signals could be identified in the P. chrysogenum supernatants and cell extracts at the growth conditions applied, 
supporting our observation that PAFB was not present at concentrations that were sufficient for detection, 
although its encoding gene was transcribed (Supplementary Fig. S3).
NMR analysis. To obtain structural information on PAFB with atomic resolution, solution nuclear magnetic 
resonance (NMR) spectroscopy experiments were performed. According to the ESI-MS data, three isoforms of 
unlabelled PAFB were present in solution. MS peak intensities (Fig. 3) and NMR of 15N-labelled PAFB suggested 
that the full-length PAFB sequence (58 residues) is the dominant form in the mixture. NMR spectra and MS 
analysis of the 15N/13C-labelled PAFB, however, identified only the shortest sequence (56 aa) (Supplementary 
Fig. S4). We named this short PAFB variant “short-form PAFB” (sfPAFB) and all aa sequence numbering below 
refers to this variant. Based on triple resonance NMR spectra, all amide HN and NH atoms could be found and 
assigned in the 15N-1H heteronuclear single quantum correlation (HSQC) spectrum of sfPAFB (Supplementary 
Fig. S5) except for Lys1 because the first N-terminal residue of proteins cannot be detected in the 15N-HSQC 
spectrum. Gly18, which resides in the middle of the big flexible loop 3, adjacent to Gly19 (Fig. 4), did not show a 
visible amide NH signal. However, other signals belonging to Gly18 were unambiguously assigned (CA and HA2, 
HA3). We note that for the 15N-labelled sample, the missing Lys1 NH signals could be found. The two overlaid 
15N-HSQC spectra of the short (15N/13C-labelled) and full-length (15N-labelled) forms of PAFB exhibited good 
agreement for most of the peaks (Supplementary Fig. S5). As our structure calculations were based on measure-
ments of the 15N/13C form, we decided to solve the structure of sfPAFB. As discussed below in more detail, there 
is no indication that the structures of PAFB and sfPAFB would exhibit differences except for the N-terminus.
The extent of backbone assignment (considering HN, HN, C’, Cα and Hα atoms in sfPAFB) reached 94.3%, and 
the extent of assigned protons including side chain hydrogens was 78.1%. During the ATNOS-CANDID-Cyana 
run 976 nuclear Overhauser effects (NOEs) were considered in the seventh cycle which resulted in an aver-
age of 17.4 NOEs/residue. The abundant distance information compared to the size of the protein resulted in 
a well-defined structure with very low backbone RMSD value of the final model (0.3 Å). Chemical shift data 
and NMR experimental parameters were submitted to the BMRB (entry no. 26001) and the structure model of 
sfPAFB was deposited in the Protein Data Bank (ID: 2NC2).
The structure of sfPAFB contains two orthogonally packed triple-stranded β-pleated sheets (Fig. 4). It should 
be noted that there are only five strands present in the protein, because the first β-strand is shared by the sheets. 
They are located between residues Gly4 and Cys6, Thr12 and Leu16, Asn21 and Asn25, His40 and Asp44 as well 
as Arg49 and Asp51, respectively. The strands are connected by three small loops (1, 2, 4) and one large loop 
(3) comprising β-turn motives (Fig. 4). Finally, the two β-pleated sheets have the following β-strand pattern: 
β1-β2-β3 and β1-β4-β5, respectively. There are six highly conserved cysteines in the amino acid sequence of 
sfPAFB in the form of three disulphide bonds between the cysteines 6 and 34, 13 and 41 as well as 26 and 52. Note 
Figure 3. Verification of purified recombinant PAFB. (a) Samples of PAFB purification steps (25 µL per lane) 
loaded on a 18% (w/v) SDS-polyacrylamide gel and silver-stained. 1, crude supernatant of 96 h-old culture; 2, 
ultra-filtrated culture broth (<30 kDa); 3, flow through of cation exchange chromatography; 4, column wash 
fraction; 5–8, elution fractions containing pure PAFB. The gel was cropped for clarity. The full-length gel is 
included in the Supplementary Information. (b) ESI-MS spectrum of purified PAFB. The x-axis represents 
the ratio between mass and charge and the y-axis represents the relative abundance of isotopes. The masses 
correspond to the different N-terminally truncated PAFB forms: the full-length (6,490.03 Da) and the two 
truncated variants, lacking either one (6,376.94 Da, -Leu) or two amino acids (6,289.91 Da, -Ser/-Leu), 
respectively. The three aa sequences below the peaks represent the N-terminus variations of recombinant PAFB.
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that this pattern (abcabc) creates a hidden central core region. While loops 1 and 4 form turn conformations, the 
secondary structure analysis showed the presence of a bend in the flexible glycine-glycine motives containing 
loop 2. The second and third β-strands are relatively hydrophobic compared to the other parts of the protein 
having no charged residues. In contrast, the central part of loop 3, the so-called large loop, contains three (32, 
33 and 35) conserved lysine residues, which, together with Lys9, form a positively charged surface region. In 
general, the large loop adopts a bent conformation, but at its C-terminal end (Asp37-Arg38) a β-turn structure is 
formed. The side-chain of Asp37 is close to those of Arg38 and Lys9, respectively. Interestingly, strand β4 in the 
middle of the second β-sheet exhibits high negative charge density. Nevertheless, there are several basic amino 
acids in its vicinity that potentially also form salt-bridges. Although both strands, β1 and β5, are relatively short, 
several H-bonds can be found between them and strand β4, stabilizing the second β-sheet. The side-chains of 
Figure 4. Comparison of the structures of sfPAFB and PAF. (a) Superimposed structure of sfPAFB (Protein 
Data Bank, ID: 2NC2, red) and PAF (Protein Data Bank, ID: 2MHV, blue). The N- and C-termini are indicated. 
(b) Superimposed structures with the lysine and arginine residues highlighted in stick representation (orange 
for sfPAFB and cyan for PAF). (c) Local RMSD calculated for the superimposed structures along the structure 
alignment generated with MAMMOTH-Mult. The position of the β-strands (β1, β2, β3, β4, β5) as assigned 
with DSSPcont are highlighted with arrows and orange backgrounds in the DSSPcont secondary structure 
labels, respectively (E for Extended, T for Turn, S for Bend, L for Loop). The three lysine residues forming a 
‘belt’ in PAF are circled in green and the corresponding positions in the alignment are boxed in green. The loop 
regions 1–4 are indicated with lines. The arrow in light grey points out the loop region with the largest local 
RMSD differences. (d) and (e) Electrostatic surface potential of PAF and sfPAFB, respectively, in corresponding 
orientations.
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Tyr43 and Tyr15 interact with each other, and together with other apolar amino acids they form a hydrophobic 
core in sfPAFB. Finally, after the fifth, amphipathic β-strand, the C-terminal region of sfPAFB does not adopt any 
particular regular secondary structure.
Despite the relatively low sequence similarity (35.2%), the structure of sfPAFB is highly similar to that of 
PAF determined previously (Protein Data Bank ID: 2MHV). Both proteins adopt a Greek key super-secondary 
structure and β-barrel global fold with identical disulphide bond pattern (abcabc). In order to compare their 
local conformation, the structures of the two proteins were superimposed. Their RMSD values were below 0.5 Å 
overall and 0.2 Å in the β-strands (Fig. 4) except for the N-terminus. However, it turned out that the conformation 
of loop 3 also shows substantial differences between PAF and sfPAFB. This was unexpected because the second 
half of loop 3 is one of the most highly conserved regions in these proteins with the longest patch of conserved 
residues (asparagine-lysine-lysine-cysteine) located here (Fig. 4), whereas the β-strands generally show a lower 
level of sequence conservation. While both of the proteins adopt a bent structure in this region, in PAF it resulted 
in a turn-like conformation both at residues Asp32-Asn33 and Asp39-Asn40 amino acids, respectively. In con-
trast, only the latter turn is present in sfPAFB at positions Asp37-Arg38. It should also be noted that although 
the high density of positive surface charges is believed to be a major contributor to the activity of PAF8, only four 
lysine residues are conserved between PAF and PAFB. Furthermore, PAFB lacks a ‘belt’ of structurally aligned 
lysine residues (Lys 6, 15, 42 in PAF) and has generally lower overall positive surface charge and a different 
surface electrostatic potential (Fig. 4). To assess the possible differences between sfPAFB and the full-length pro-
tein, we built a first-approximation structural model of full-length PAFB by adding a leucine-serine segment to 
the N-terminus of the experimental sfPAFB structure. Short molecular dynamics (MD) runs suggest that the 
full-length N-terminus might align to strand β4 (residues 41–45) to form an N-terminal β-strand longer than in 
the sfPAFB form similar to the case of PAF (Supplementary Fig. S6). This is also plausible based on the favourable 
interaction between Lys1 and Asp42 (sfPAFB numbering) formed during the MD calculations. Nevertheless, 
we do not expect that the structures of sfPAFB and full-length PAFB exhibit substantial differences. Finally, the 
variation of the N-terminus does not dramatically change the biophysical features of the PAFB forms, such as 
isoelectric point (pI), net charge and the grand average of hydropathy (GRAVY) (Supplementary Table S1).
Antifungal activity of PAFB. The growth inhibitory activity of PAFB was tested on filamentous fungi, 
yeasts and bacteria in 96-well microtiter plate assays by determination of the minimal inhibitory concentration 
(MIC) (Table 1). PAF was used as a control and for comparison. Among the filamentous fungi tested, the model 
organism Neurospora crassa showed the highest PAFB-sensitivity (MIC 0.12 µM in 0.1 × PDB), followed by the 
opportunistic human pathogens Aspergillus fumigatus (MIC 0.25 µM), Trichophyton rubrum (MIC 0.5 µM), and 
Aspergillus terreus (1 µM). Interestingly, low doses of PAFB (0.5 µM) had self-inhibition activity on the producing 
strain P. chrysogenum Q176 in 0.1 × PDB. This stands in contrast to PAF, which did not affect the germination of 
P. chrysogenum at the concentrations tested.
So far, no anti-yeast activity has been reported for PgAFP in malt extract broth19 and for PAF in YPD 
medium26. We found, however, a clear inhibitory activity for PAFB and PAF at MICs of 1 µM and 2–4 µM on the 
model yeast Saccaromyces cerevisiae and the opportunistic human pathogen Candida albicans, respectively, when 
cultivated in 0.1 × PDB. In contrast, no anti-bacterial activity of PAFB could be observed in the administered 
concentration range (0–32 µM) on the Gram-negative Escherichia coli and the Gram-positive Bacillus subtilis, 
which is similar to what is found for PAF.
PAFB efficiently prevented the conidial germination of all tested filamentous fungi at the respective MIC, 
except for N. crassa. Similar to previous observations with PAF27, N. crassa conidia still germinated in the pres-
ence of PAFB, but the elongation of the germ tubes was inhibited irrespective of the culture medium applied 
(0.1 × PDB or 0.2 × Vogel’s). The growth inhibitory activity of PAFB was further characterized for N. crassa 
0.2 × Vogel’s medium, in which PAFB exhibited a comparable MIC as in 0.1 × PDB (Table 1). N. crassa conidia 
Organisms
MIC [µM]
PAFB PAF
Filamentous fungi
A. fumigatus 0.25 1
A. niger 0.50 0.25
A. terreus 1 32
N. crassa 0.12/0.25§ 0.06/0.06§
P. chrysogenum 0.50 >32
T. rubrum# 0.5 0.25
Yeasts
C. albicans 1 4
S. cerevisiae 1 2
Bacteria
E. coli >32 >32
B. subtilis >32 >32
Table 1. Minimal inhibitory concentrations (MIC) of PAFB and PAF on fungi and bacteria. §0.2 × Vogel’s 
medium. #Due to slow proliferation rate the MIC of T. rubrum was determined after 8 days of incubation.
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exposed to 0.25 μM PAFB for 6 h in 0.2 × Vogel’s medium germinated at a significantly lower rate (53.14 ± 5.70%, 
p < 0.0001) than the untreated control (83.30 ± 2.69%) (Table 2). PAF-exposure, by contrast, did not influence 
the germination efficiency, as 85.56 ± 1.07% of the conidia germinated in the presence of 0.06 µM PAF compared 
to the untreated control (Table 2).
Furthermore, PAFB significantly reduced the germ tube length of 6 h old germlings to 17.99 ± 2.41 µm at 
its MIC, which corresponded to a reduction of −70% compared to the untreated control (60.32 ± 10.04 µm, 
p < 0.0001). By contrast, PAF reduced the germ tube length less severely at its MIC (48.22 ± 7.34 µm; p ≤ 0.05; 
−20% compared to control) (Table 2). The increase of the PAFB and PAF concentration to 2 × MIC, respectively, 
did not further aggravate these effects on N. crassa (data not shown). Thus, our findings indicated that PAFB 
affects colony establishment of N. crassa more effectively than PAF.
It is of great relevance that an antifungal drug acts fungicidal rather than fungistatic to reduce the risk of 
resistance development, which occurs more readily with drugs showing fungistatic activity. We therefore tested 
the fungicidal potential of PAFB and PAF on the wide-spread human opportunistic pathogen C. albicans, which 
causes candidiasis. To this end, C. albicans cells were incubated with the antifungal proteins at concentrations 
corresponding to 0.25–4 × MIC for 0 h (control), 6 h and 24 h in 0.1 × PDB and were then plated in appropriate 
dilutions onto PDA plates to allow surviving cells to establish colonies.
As shown in Fig. 5a, viability was significantly reduced after 6 h of incubation in the presence of PAFB in a 
dose-dependent manner. The survival rate was 38.33 ± 4.49% (p < 0.0001) at 0.25 µM, 13.74 ± 3.16% (p < 0.0001) 
at 1 µM and 9.81 ± 7.24% (p < 0.0001) at 4 µM compared to the viability of the respective controls (0 h of incu-
bation) which were set to be 100%, respectively. The fungicidal potential was further increased when C. albicans 
cells were exposed to PAFB for 24 h. Compared to the survival rate of the controls (100%), only 11.24 ± 3.07% 
(p < 0.0001), 13.45 ± 10.79% (p < 0.0001) and 3.08 ± 2.99% (p < 0.0001) cells survived when exposed to 0.25, 1 
and 4 µM, respectively (Fig. 5a).
Germination efficiency 
[%]a,b Germ tube length [µm]b
control 83.30 ± 2.69 60.32 ± 10.04
PAFB 53.14 ± 5.70** 17.99 ± 2.41**
PAF 85.56 ± 1.07 48.22 ± 7.34*
Table 2. The effect of the MIC of PAFB and PAF on the colony establishment of N. crassa. aThe germination 
efficiency is indicated in (%) compared to the total conidial count used, which was set to be 100%. bThe 
values are given as mean ± SD (n = 3). Significant differences (p-values) between values were determined by 
comparison with the untreated control.*p ≤ 0.05, **p < 0.0001.
Figure 5. Antifungal effect of PAFB and PAF on C. albicans. Cells were exposed to 0.25 × MIC, 1 × MIC and 
4 × MIC of (a) PAFB and (b) PAF. Samples at appropriate dilutions were plated on 0.1 × PDA after 0 (control), 
6 and 24 h of incubation and the number of colony forming units was determined after 24 h. Colony numbers 
counted without incubation (0 h) were set as 100%. Values represent the mean ± SD (n = 6). Significant 
differences (p-values) between values were determined by comparison with the respective survival rate at 0 h. 
*p < 0.001, **p < 0.0001.
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Similarly, C. albicans cells exposed to PAF showed reduced viability after 6 h of incubation (Fig. 5b). The fun-
gicidal effect of PAF, however, was less pronounced than that with PAFB. The survival rate was 70.21 ± 10.17% 
(p < 0.001) at 1 µM PAF, 38.35 ± 7.92% (p < 0.001) at 4 µM PAF and 24.21 ± 6.88% (p < 0.0001) at 16 µM PAF, 
which corresponded to 0.25 × MIC, 1 × MIC and 4 × MIC, respectively, compared to the control cells (100% 
survival at 0 h of incubation) (Fig. 5b). This fungicidal effect was detectable with 4 µM and 16 µM PAF at longer 
incubation times (survival rates after 24 h: 31.48 ± 15.05% (p < 0.001) and 19.65 ± 17.68% (p < 0.001), respec-
tively) (Fig. 5b), whereas PAF was less effective at low concentration (0.25 × MIC) and with shorter incubation 
times (6 h). Candida cells exposed to 1 µM PAF proliferated further when cultivated for 24 h in liquid 0.1 × PDB, 
which became evident from the increased number of colony forming units when plated on PDA plates.
Our results indicate that PAFB acts fast and efficiently in a fungicidal way on C. albicans at a sub-MIC 
concentration.
Localization of PAFB in fungi. In previous studies, we reported that PAF toxicity in sensitive fungi is 
closely linked with its active internalization into the cell8,22. Therefore, we examined the uptake and localization 
of PAFB in comparison to PAF in N. crassa, P. chrysogenum and C. albicans. For this purpose, PAFB and PAF 
were labelled with the green fluorescent dye BODIPY. Both proteins had comparable labelling efficiencies and the 
antifungal activity was similar to that of the unlabelled proteins (data not shown). To visualize the fluorescence 
signals 8 µM of protein conjugates were applied.
The conidia of N. crassa and P. chrysogenum were allowed to germinate for 12 h, the cells of C. albicans to grow 
for 6 h in the presence of BODIPY-PAFB and BODIPY-PAF, respectively, before the fungal cells were co-stained 
with propidium-iodide (PI) to test cell viability. As shown in Fig. 6(b,c), both BODIPY-labelled proteins localized 
in germlings of N. crassa and in C. albicans cells, which undoubtedly showed signs of cell death by positive PI 
staining. The same was observed with P. chrysogenum germlings, in which BODIPY-PAFB uptake correlated with 
PI staining. By contrast, we did neither detect BODIPY-PAF uptake nor PI staining in P. chrysogenum (Fig. 6a). 
These observations matched with the different susceptibilities of P. chrysogenum for PAFB and PAF described 
above (Table 1) and provide further evidence that antifungal toxicity of PAFB and PAF is closely linked to their 
uptake into fungal cells.
We further analysed the uptake mechanism of BODIPY-PAFB in N. crassa in time course experiments. After 
30 min of incubation, BODIPY-PAFB had already attached to the envelope of N. crassa conidia and intracellular 
signals were visible (Fig. 7). With prolonged incubation time (>2 h), the PAFB signals in the cytoplasm steadily 
increased which coincided with positive PI staining (Fig. 7). Interestingly, fungal cells showed no signs of cell 
death as long as BODIPY-PAFB resided in vacuoles (Fig. 7).
We investigated in the next step whether PAFB enters the cells actively or passively, e.g. by diffusion. To 
this end, we exposed 4.5 h-old germinated conidia to NaN3 and carbonyl cyanide m-chloropheylhydrazone 
(CCCP), which are inhibitors of oxidative phosphorylation and ATP production, respectively, for 30 min before 
BODIPY-PAFB was added for further 1.5 h of incubation.
As shown in Fig. 8, BODIPY-PAFB remained attached to the outer layers and was not taken up into the N. 
crassa cells in the presence of the inhibitors (Fig. 8). In contrast, BODIPY-PAFB localized in the vacuoles of 
germlings that were not exposed to the inhibitors (Fig. 8). PAFB uptake was also inhibited at 4 °C, which reduces 
cell metabolism (data not shown).
Figure 6. Uptake of BODIPY-PAFB and BODIPY-PAF in germlings of (a) P. chrysogenum, (b) N. crassa and 
(c) C. albicans cells. Samples were taken after 12 h of incubation of conidia of P. chrysogenum and N. crassa 
and after 6 h of incubation of C. albicans cells with BODIPY-labelled proteins. Co-staining with PI was applied 
10 min before imaging. BF = Brightfield, BP = BODIPY-labelled proteins. Scale bars = 30 µm in (a,b), scale 
bar = 15 µm in (c).
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These observations proved the staining specificity of BODIPY-PAFB and indicate that the internalization of 
BODIPY-PAFB depends on an active cellular metabolism. Negative PI staining confirmed the viability of the cells 
under the applied test conditions.
Figure 7. Uptake of BODIPY-PAFB (8 µM) in N. crassa conidia or germlings. Samples were taken after 30 min, 
2 h and 8 h and co-stained with PI for 10 min before imaging. White and black arrows indicate BP-PAFB specific 
signals in vacuoles. BF = Brightfield, BP = BODIPY-labelled PAFB. Scale bar = 15 µm.
Figure 8. Uptake of BODIPY-PAFB (8 µM) in N. crassa germlings in the presence of 100 µM CCCP or 2.5 mM 
NaN3. The control was stained with BODIPY-PAFB without inhibitors. All samples were co-stained with PI for 
10 min before imaging. BF = Brightfield, BP = BODIPY-labelled PAFB. Scale bar = 15 µm.
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Antiviral activity. Recently, Holthausen et al. (2017) reported about the efficacy of host defense peptides 
from the skin of the South Indian frog to treat respiratory viral infections, as in the case of human influenza A 
viruses28. In this study, we examined the selective anti-viral potential of PAFB and PAF to reduce the infection 
of human epithelial cell line L132 by the human coronavirus strain 229E (HCoV 229E) in vitro. First, we con-
firmed that PAFB, similarly to PAF, showed no cytotoxic effects on the host cells in the applied concentration 
range (0–32 μM) (Supplementary Fig. S7). The anti-viral activity of the proteins was expressed in terms of protein 
concentration that protects against virus-induced cytopathogenic effects (CPE) in L132 cells, such as syncytia 
formation, vacuolization, cell rounding, detachment and cell death (Fig. 9a). We determined 8 μM as the min-
imum effective protein concentration that reduced virus-induced CPE and preserved cell monolayer integrity 
(Fig. 9a,b). The anti-viral efficiency could be observed in virus infected L132 cells at different viral titres (multi-
plicity of infection (MOI) 1–0.01) (Supplementary Fig. S8), but reached a maximum inhibition value of 21.07% 
with PAFB against HCoV 229E at MOI 0.01 (Fig. 9b). PAF in contrast, inhibited HCoV 229E-induced CPE less 
effectively than PAFB, while still exhibiting antiviral activity, especially at lower viral titers: 8 μM PAF reduced the 
viral CPE to 11.89% at MOI 0.01 (Fig. 9a,b). The application of higher protein concentrations (16 μM and 32 μM), 
however, did not further increase the anti-viral effect of PAFB and PAF (Supplementary Fig. S8). The anti-viral 
efficacy of both proteins was also confirmed by immunofluorescence experiments, where 8 μM PAFB and PAF 
successfully reduced the number of HCoV 229E infected L132 cells (Fig. 9c). HCoV 229E localization was exam-
ined with a virus-specific antibody at 72 h post infection when viral replication and transcription was underway. 
As shown in Fig. 9c, a strong virus-specific green fluorescent signal was observed in the majority of HCoV 229E 
infected cells (MOI 0.01) without PAFB or PAF treatment. The signal intensity and the number of virus infected 
cells significantly decreased in the presence of PAFB or PAF (Fig. 9c). This observation suggests that the antiviral 
effect of the proteins may reduce not only the final stages of the viral replication cycle and CPE, but also the earlier 
steps of the infection and/or the spread of the viral particles.
Discussion
In this study, we provide detailed insight into the antimicrobial activity and the structure of the secreted PAFB 
protein from the penicillin-producing mould P. chrysogenum Q176. This protein belongs to the group of small, 
cysteine-rich and cationic proteins from ascomycetes. Although the PAFB encoding gene was abundantly tran-
scribed, we could not detect the translated gene product under the cultivation conditions applied. This phe-
nomenon is not unique. Only recently, Garrigues et al. (2016) reported that the identification of the genome 
encoded antifungal protein AfpB from Penicillium digitatum had failed, although the gene was transcribed at high 
level18. Instead the antifungal activity of this cryptic protein was successfully analysed by mapping the antifungal 
motifs of AfpB with synthetic cysteine-containing peptides29 before recombinant, full-length AfpB was generated 
Figure 9. PAFB and PAF reduced CPE of HCoV 229E in L132 cells. PAFB and PAF (8 µM, respectively) were 
applied. (a) Crystal violet assay visualized the reduction of virus-induced CPE at MOI 0.01. (b) Reduction of the 
viral CPE at MOI 1, MOI 0.1 and MOI 0.01 at 72 h post infection in the presence of PAFB and PAF (0, untreated 
control). (c) Immunostaining of HCoV protein in L132 cells with mouse-anti hexon antibody and goat anti-
mouse FITC-labelled secondary antibody after treatment with PAFB and PAF. Nuclei of fixed L132 cells were 
counter-stained with Hoechst 33342. Virus-uninfected cells (Mock) served as a negative control and virus 
infected cells without protein treatment as positive control (HCoV 229E); *p < 0.05; **p < 0.01.
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recently for functional analysis applying the P. chrysogenum-based expression system20,30. The reason remains 
obscure, why the timely expressed and correctly processed pafB mRNA was not translated into detectable protein 
amounts by P. chrysogenum Q176. As conidia of P. chrysogenum were PAFB susceptible, it seems that the produc-
tion of PAFB needs strict regulation to avoid self-limitation. On the other hand, the pre-existing pool of mRNA 
may serve as a reservoir allowing for fast availability in case of urgent needs, e.g. a fast response to changing envi-
ronmental or developmental stimuli. Indeed, a function of cysteine-rich, cationic proteins beyond fungal growth 
inhibition, such as stress response and asexual development, supporting the fitness of the producing moulds 
has been reported earlier21,31. A recently published transcriptome meta-analysis for the expression regulation of 
the Aspergillus niger antifungal protein AnAFP further underlines the role of these proteins in stress response, 
growth and development, nutrient recycling, and autophagy32. Thus, the pafB mRNA may be stored, for example 
in processing bodies or stress granules as described for S. cerevisiae and mammalian cells, until the PAFB protein 
is needed33–35. We are currently investigating this assumption.
We applied the P. chrysogenum-based expression system to generate PAFB in sufficient quantity and high 
quality for functional and structural analyses. The strong paf promoter, the presence of multiple gene copies and/
or possibly the genomic integration site are responsible for the bulk production of recombinant PAFB20,36. The 
fact that recombinant PAFB was produced in P. chrysogenum ∆paf without problems indicates that regulatory 
elements, likely present in the 5’- and/or 3’- regions of the pafB mRNA and responsible for controlling mRNA 
translation and/or storage in the wild-type, were replaced in the pafB expression cassette.
Mature PAFB was purified in a major full-length form with 58 aa, and two less abundant short variants with 
57 aa and 56 aa, respectively. Another member of this protein group, the Aspergillus giganteus AFP, is secreted in 
two naturally occurring N-terminal variants, the major short form (51 aa) and in lower amounts the larger form 
(lf-AFP), containing six additional N-terminal amino acids37. Lf-AFP remarkably differs from AFP in pI, GRAVY 
and net charge and shows lower antifungal activity37,38. To date, we cannot tell whether the N-terminal PAFB 
variants occur naturally, e.g. by autocatalytic activities, or whether they are a consequence of overexpression 
conditions. The latter has been observed for example, for the expression of the recombinant bovine chymosin 
in Aspergillus awamori, which resulted in products with variable N-termini, most likely due to proteolysis in 
the culture supernatant39. Recombinant PAF produced in high yields in P. chrysogenum showed no N-terminal 
variations whereas subtle N-terminal differences were detected when expressed in P. digitatum20. Similarly, AfpB 
expression in P. digitatum using the paf-derived expression cassette resulted in gene products with N-terminal 
variations30. In none of these cases, however, the antifungal activity of the N-terminal variants was affected20,30. 
Proteolysis of the PAFB N-terminus might be influenced by the nutrient composition of the fermentation broth. 
For double isotope labelling (15N/13C) of PAFB, sucrose was replaced with 13C-glucose as carbon source in the 
growth medium, which might be responsible for the generation of sfPAFB (56 aa). This assumption requires fur-
ther analysis in the future. In one of our recent studies, we demonstrated that the N-terminal aa regulate the sta-
bility, folding and antifungal function of the recombinant NFAP protein from Neosartorya fischeri40. By contrast, 
we found here, that the N-terminal PAFB variants do not differ significantly in their overall solution structure and 
physico-chemical features. We therefore assume that the antifungal activity is not affected.
Importantly, the mature full-length PAFB is identical to the mature PgAFP described from P. chrysogenum 
RP42C, originally isolated from cured ham41. PgAFP was shown to be sensitive to the ionic strength of the fungal 
culture medium42, and highly stable under extreme pH, high temperature and against proteolysis19. This is also 
true for other members of this antifungal protein group, such as PAF, AFP, or NFAP, which possess a highly stable 
disulphide-bond mediated, compact, β-fold structure9,40,43.
PAFB showed potent antifungal activity against model fungi and human fungal pathogens in low concen-
trations (µM range). PAFB prevented more effectively than PAF the germination and colony establishment of 
N. crassa, and significant differences in the susceptibility of some tested fungi, e.g. A. terreus, P. chrysogenum, 
point towards different modes of action of these two proteins. Variations in the antifungal spectrum and the 
mode of action were reported for the structurally very similar, related antifungal proteins PAF, AfpB, NFAP and 
AFP26,30,44,45. We propose that the presence and activity of host interaction molecules that regulate the uptake 
mechanism, the processing of signals and the ability to cope with detrimental effects triggered by the antifungal 
proteins determine the susceptibility of fungal species. Furthermore, the importance of protein surface charges 
and their distributions described for PAF function need to be considered to explain differences in the antifungal 
activity8.
Recombinant PAFB was identified after 72 h of cultivation and reached its maximum amount after 96 h in 
the standard medium MM, which perfectly coincided with the onset of production of PAF and other recombi-
nant PAF variants that had been generated with this expression system under the control of the paf promoter20. 
Interestingly, the overproduction of recombinant PAFB did not affect the proliferation of the producer strain P. 
chrysogenum pafB, although an inhibitory activity was observed on conidia in the microdilution assays (Table 1). 
One possible explanation for this phenomenon could be that under PAFB expression conditions (established 
hyphal growth and MM), P. chrysogenum hyphae lack any PAFB susceptibility determinants, which, in contrast, 
must be present in 0.1 × PDB. Indeed, we proved that PAFB, similarly to PAF, did not interact with P. chrysoge-
num hyphae cultivated in MM (Supplementary Fig. S9). Only when grown in 0.1 × PDB, hyphal proliferation was 
inhibited and PAFB was taken up by the cells (Supplementary Fig. S9). PAF, on the other hand, neither interacted 
with P. chrysogenum conidia nor hyphae, irrespective of the culture medium applied (Table 1 and Supplementary 
Fig. S9).
Similar nutrient dependent susceptibility for PAFB and PAF was observed with yeasts. Up to date, potent 
anti-yeast activity was only reported for the N. fischeri protein NFAP2, which killed yeast cells within minutes by 
plasma membrane disruption1. Neither for PgAFP19, nor for the related proteins AFP, NFAP and PAF any yeast 
inhibitory activity was ever found1,46. Most interestingly, in this study we show for the first time, anti-yeast activity 
of PAFB and PAF in 10 × diluted PDB. Apparently, yeast cells exhibit susceptibility determinants for both proteins 
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when cultivated in this “starvation” medium. The time course experiments indicated that C. albicans cells were 
not killed immediately after administration of PAFB and PAF, but that cell death occurred in a time and concen-
tration dependent manner, supporting our observations made so far that exclude a fast killing mechanism, e.g. by 
pore formation, but point towards more complex interaction mechanisms with the target cell8,27.
Indeed, cell toxicity of PAFB in all susceptible fungi studied correlated with active protein internalization and 
its subsequent distribution in the cytoplasm, which coincided with PI positive staining as observed with PAF and 
other antifungal peptides and proteins in previous studies8,22,47–49. Higher fungicidal activity of PAFB over that of 
PAF might result from differences in efficient uptake and/or reaching an effective killing concentration within the 
cell. Further investigations are needed to elucidate the mechanisms that regulate fungal susceptibility and killing 
kinetics of members of this protein group.
Few studies were published on the anti-viral activity of antimicrobial peptides and proteins expressed by 
animals and plants, e.g. defensins50–52. A surprising and novel observation for small, cysteine-rich, cationic and 
antimicrobial proteins of fungal origin was the efficacy of PAFB and PAF against HCoV 229E virus. This virus is 
highly contagious and can cause mild, cold-like respiratory illness. However, highly pathogenic HCoVs such as 
severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) 
predominantly infect lower airways and cause fatal pneumonia with high morbidity and mortality during an epi-
demic53. Anti-HCoV drugs and vaccines are in different stages of development, but they are still lacking today54. 
PAFB and PAF, preferentially at low MOI, reduced the virus-induced CPE of infected human L132 cells, thus 
promising a potential alternative therapeutic approach against human coronaviruses. Based on the data collected 
in this study, we suggest that PAFB and PAF directly - or indirectly by influencing the host cell metabolism - 
inhibit the release and spread of progeny virus particles, or destroy the HCoV virions. The observed slight differ-
ences in the anti-viral activity between PAFB and PAF may result from different virus or host cell susceptibility 
towards both proteins, or from differences in the protein surface charge distributions as outlined above. The 
observation that anti-viral efficacy could not be further increased with higher protein concentrations than 8 µM 
could be attributed to low bioavailability of the proteins at higher concentrations, a partial clustering or hampered 
crossing of bio-membranes as shown for antimicrobial proteins in previous studies55,56. Work is currently in pro-
gress to get detailed insight into the mode of the anti-viral action of PAFB and PAF.
Importantly, lethal activity of the potential drugs towards human cells has to be excluded and harmful side 
effects need to be kept to a minimum for future antimicrobial drug development. Similar to AFP and PAF10,57, 
no toxic activity on mammalian cells was detected for PAFB in vitro (Supplementary Fig. S7). This feature and 
the antifungal/antiviral potential render PAFB a promising candidate for the development of novel antimicrobial 
treatment strategies.
Methods
Strains, media and cultivation conditions. Microbial strains used in this study and growth media are 
listed in the Supplementary Table S2 and Table S3, respectively.
The propagation of vectors and plasmids was carried out in E. coli DH5α, grown in lysogeny broth medium 
(LB), supplemented with 100 µg/mL ampicillin. Yeasts were grown on potato dextrose agar (PDA, Becton 
Dickinson) or on solid yeast extract peptone dextrose medium (YPD) at 37 °C.
For the generation of conidia, P. chrysogenum was cultivated on solid defined minimal medium (MM) at 
25 °C, N. crassa on Vogel’s agar plates at 37 °C under continuous light and A. fumigatus, A. niger and A. terreus 
were grown on PDA (Becton Dickinson) at 37 °C. T. rubrum was grown on oatmeal agar. Conidia were harvested 
in spore buffer (0.9% NaCl (w/v), 0.01% Tween 80 (v/v)). For transformation, 108 conidia of P. chrysogenum 
Δpaf21 were grown in 200 mL CM for 38 h at 25 °C under continuous shaking (210 rpm). Conidia (1–2 × 108) 
of P. chrysogenum Q176 and P. chrysogenum pafB were cultivated in 200 mL MM for 24–144 h at 25 °C under 
continuous shaking for Northern, Southern and Western blot analyses and PAFB production, respectively. PAFB 
single (15N) or double (15N/13C) isotope-labelling for NMR analysis was carried out by replacing the nitrogen and/
or carbon source in MM by 0.3% Na15NO3 and/or 1% 13C-glucose (w/v) (Euriso-Top), respectively.
Northern analysis. Total RNA was isolated from P. chrysogenum Q176 liquid cultures using TRI Reagent 
(Sigma-Aldrich). Ten µg RNA per lane were loaded on 1.2% formaldehyde-agarose gels, blotted onto Hybond-N 
membranes (Amersham Biosiences) and hybridized with digoxigenin (DIG)-labelled probes (Roche). The primer 
pair opafB_fw/opafB_rev and opaf1_fw/opaf_rev was used for PCR-based amplification of the pafB and paf spe-
cific hybridization probes, respectively (Supplementary Table S4).
Fungal transformation and verification of plasmid integration. For the generation of a 
PAFB-overproducing P. chrysogenum strain, the paf deletion mutant P. chrysogenum Δpaf 21 was transformed 
with pSK275pafB. Protoplast formation and transformation of 10 µg PstI linearized pSK275pafB was carried out 
according to Cantoral et al.58. Transformants were single spored three times on MM agar supplemented with 
0.3–0.6 µg/mL pyrithiamine hydrobromide (Sigma-Aldrich).
Positive transformants were analysed by Southern blotting for the genomic integration of pSK275pafB20. A 
detailed description is given in the Supplementary Methods.
Protein expression, purification and verification. PAFB and PAF were produced and purified from 
the cell-free supernatant as recently described20. To verify the identity of purified PAFB, the protein mass was 
determined by ESI-MS at the Protein Micro-Analysis Facility (Medical University of Innsbruck)20. In addition, 
protein solution was size-fractionated on a 18% (w/v) SDS-PAGE as described20.
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NMR analyses. Three PAFB samples were prepared for NMR studies: an unlabelled, a 15N-labelled and a 
15N/13C-labelled as described recently20. Lyophilized protein was dissolved in 20 mM acetate buffer (prepared with 
deuterated acetic acid, pH = 4.5) and filled into Shigemi NMR sample tube (250 µl). Protein concentration was set 
to 1.5 mM. Protein resonance assignment was accomplished with the same strategy that was applied previously for 
double-labelled PAF6. Briefly, 2D 15N-HSQC served as the root for the following 3D triple resonance experiments: 
HNCO, HN(CA)CO, HNCA, HN(CO)CA, HNCACB, HNHA, HBHA(CO)NH and HN(CO)CACB, which were 
used for obtaining backbone signal assignments59. For resonance assignment of side chains the combination of 
HC(C)H COSY, HC(C)H TOCSY, HCC(CO)NH and (H)CCH-TOCSY experiments were used, and aromatic 
protons were identified with the aid of 2D CB(CGCD)HD and CB(CGCDCE)HE spectra. The applied exper-
iment versions were identical with those described in our previous study6. To collect NOE distance restraints, 
15N- and 13C-resolved 3D NOESY spectra were recorded as well as a 2D 1H-1H NOESY this latter experiment was 
performed on the unlabelled PAFB sample. All the above listed measurements were recorded on a Bruker Avance 
II 500 spectrometer equipped with TXI z-gradient probe-head. The NOESY-type experiments were repeated 
on a 700 MHz spectrometer with similar configuration. The higher spectral resolution of the NOESY spectra 
with less overlapping cross-peaks help obtaining more distant restraints for structure calculation. All spectra 
were acquired at 298 K and data was processed with Topspin 3.0 software. Sequential resonance assignment was 
performed with the aid of CARA 1.8.4 software from which chemical shift data was exported to other software. 
Cyana 2.1 torsion angle dynamics package60,61 was used for de novo structure determination in combination 
with the ATNOS-CANDID algorithm (the latter was used for peak picking and NOE assignment). Setup files 
for Cyana were prepared manually. Disulphide connections were defined in the Cyana input assuming abcabc 
disulphide pattern as in PAF (linking cysteine 8–36, 15–43 and 28–54). Diastereotopic protons for non-equivalent 
CH2 groups were considered as stereo-chemically ambiguous assignments. Backbone torsional angle constraints 
were predicted according to TALOS+62 and were used for the refinement of the structure model. Seven cycles 
of Cyana iterations were performed, and the 20 lowest energy conformers were considered as a final structure 
model. Chemical shift data and NMR experimental parameters were submitted to the BMRB databank and the 
structural ensemble was uploaded to Protein Data Bank (ID: 2NC2).
Antibacterial and antifungal activity assays. Growth inhibition assays were performed in 96-well micr-
otiter plates (Nunclon Delta, Thermo Scientific). Conidia or yeast cells (104/mL) were incubated in 0.1 × PDB 
(Becton Dickinson) with increasing concentrations of PAFB (0–32 µM) in a total volume of 200 µL at 25–30 °C. 
Bacteria were pre-cultivated in 0.1 × LB or 0.1 × PDB to reach OD620 of 0.05 and then exposed to antimicrobial 
treatment (0–32 µM PAFB) at 37 °C. Microbial growth was monitored after 24–48 h by measuring the OD620 with 
a Fluostar Omega microplate reader (BMG Labtech) and microscopically using an inverted microscope (Leica 
DM IL Led, Leica Microsystems). Images were taken with an AxioCam MR digital camera (Carl Zeiss GmbH) 
and processed with AxioVision software (Carl Zeiss GmbH). The MIC was defined as the minimal protein con-
centration that inhibited growth by ≥90% compared to the untreated control which was referred as 100% growth.
The germination efficiency and germ tube length of N. crassa in the presence of PAFB at its MIC was deter-
mined as described8.
Fungistatic and fungicidal effects on C. albicans were determined by incubating 2 × 104 cells per mL in 
0.1 × PDB with 0–4 µM PAFB at 30 °C with shaking for up to 24 h. Samples were taken after 0 h, 6 h and 24 h, 
diluted in 0.1 × PDB and plated on PDA plates in duplicates. The number of colony forming units was determined 
after incubating the plates for 24–48 h at 37 °C. The survival rate was calculated by setting the colony forming 
units at time point 0 h as 100%.
In all experiments 0–32 µM PAF was applied for comparison. Experiments were prepared in technical tripli-
cates and performed at least twice.
Uptake and localization studies. The green fluorophore BODIPY FL EDA (Life Technologies) was used 
for protein labelling as described by Sonderegger et al.8.
To study the protein uptake into C. albicans, P. chrysogenum and N. crassa, 106 yeast cells/mL or conidia/
mL were incubated with 8 µM BODIPY-labelled proteins in the respective media (0.1 × PDB, 0.2 × Vogel’s) at 
25–30 °C and analysed within an incubation time of 30 min to 12 h. To investigate PAFB uptake into P. chrysoge-
num hyphae grown in MM, 24 h old mycelia were stained with 8 µM BODIPY-labelled PAFB for 2.5 h.
Co-staining with 5 µg/mL PI for 10 min at room temperature was carried out to monitor the viability of fungal 
cells. For positive staining controls, samples were treated with 50% (v/v) ethanol for 30 min.
PAFB-transport into hyphae was investigated in N. crassa. Conidia (5 × 105/mL) were grown in 0.2 × Vogel´s 
medium for 4.5 h at 25 °C and then further incubated at 4 °C or with 2.5 mM NaN3 (Sigma-Aldrich) or 100 µM 
CCCP (Sigma-Aldrich) for 30 min, respectively. BODIPY-labelled PAFB (8 µM) was added and the samples were 
microscopically analysed after 1.5 h of incubation.
Microscopic imaging was performed with a fluorescence microscope (Axioplan, Carl Zeiss GmbH), equipped 
with an AxioCam MR3 camera (excitation/emission filters 500/535 nm for green fluorescence, 546/590 or 
565/620 nm for red fluorescence, Carl Zeiss GmbH). Image processing and editing was done with Axiovision 
(Carl Zeiss GmbH), GIMP (GNU Image Manipulation Program, version 2.8.20; www.gimp.org) and Microsoft 
Power Point (Microsoft Corp.).
Antiviral activity assays
Cultivation of human epithelial cell line L132. For virus propagation L132 cells were grown in anti-
biotic-free Dulbecco’s Modified Eagle Medium with nonessential amino acids (Thermo Fisher Scientific) com-
plemented with 10% fetal bovine serum (FBS, Eurobio). For the antiviral assays the same medium was used, 
containing only 2% FBS.
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Viruses. The human coronavirus HCoV 229E was propagated and quantified in L132 cells. Initial virus titers 
were calculated as 50% cell culture infectious doses (CCID50/mL), according to Reed and Muench (1938)63. All 
virus stocks were stored at −70 °C until used.
Antiviral tests. The antiviral activity of PAFB and PAF was determined by evaluating the reduction of the 
virus-induced CPE, characterized by rounding, vacuolization, syncytia formation and cell death of the cell mon-
olayer. One day before infection, 1 × 104 L132 cells/well were seeded into a 96-well culture plate. The next day, 
medium was replaced by fresh medium containing diluted virus suspension at MOI 0.01–1.0 was added to the 
cell culture, followed by the immediate addition of cell culture medium supplemented with 2% FBS and 0–32 µM 
PAFB or PAF. Plates were then incubated at 33 °C, 5% CO2, for HCoV 229E strain, and checked for virus-induced 
CPE after 24 h and 72 h, using an inverted light microscope AE2000 (Motic).
The antiviral activity of the proteins was determined by the crystal violet assay, adapted from Feoktistova et al.64. 
Antiviral activity was expressed as the percentage effective CPE-inhibitory concentration. Modification of the cell 
morphology and reduction of the virus-induced CPE were also microscopically determined. Three independent 
experiments were carried out in triplicate.
For immunofluorescence staining, L132 cells were fixed in 3.7% (v/v) formaldehyde (Sigma-Aldrich) and sub-
sequently immersed in PBS containing 0.1% (v/v) Triton X-100 for cell permeabilization. Samples were blocked 
in PBS/3% BSA (w/v) (Sigma-Aldrich). Hoechst 33342 (Thermo Fischer Scientific) was used as nuclear coun-
terstains for fixed cells. The viral capsid was detected by mouse monoclonal anti-hexon antibody (1:100) (Santa 
Cruz Biotechnology) diluted in PBS/3% (w/v) BSA. Primary antibodies were incubated on the fixed cells for 
90 min at room temperature, washed, and the antigen-antibody complexes were detected with goat anti-mouse 
FITC-labelled secondary antibody (1:1,000) (Santa Cruz Biotechnology) according to Grigorov et al.65. Images 
were acquired using an inverted epifluorescence microscope (Axio Observer 3, Carl Zeiss GmbH). Imaging and 
image processing was routinely performed with ZEN software (2009, Carl Zeiss GmbH) or ImageJ (The ImageJ 
ecosystem: An open platform for biomedical image analysis)66.
Statistical analyses. Statistical analysis was performed using Microsoft Excel 2010 software (Microsoft 
Corp.). Two sample t-test with equal variance and one-tailed distribution was used.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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